FAIR VALUE @ 0.077, page-48

Seems to me that MXC has a lot more going for it than AC8. Technically MXC seem further advanced in their research, they are running trials on epilepsy (something that is unlikely to have been approved by authorities lightly) have an association with a Sydney university research facility, have a separate improving cashflow from skin care products proven to also be effective for psorarisis along with other factors already discussed in these threads over the last month.
And yet AC8 since Feb 21st has had an increase of 250% c/f MXC 89.74%. If the only difference is the license to import CBD etc then all things equal, we might expect that MXC after receiving a similar license should have a jump in SP to at least 9.75c?